1-8 of 8
Keywords: Safety
Close
Follow your search
Access your saved searches in your account

Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles
Subject Area:
Dermatology
Kompass Dermatol (2024) 12 (2): 88–89.
Published Online: 08 April 2024
...Irena Neustädter; Sophie Blatt Background: For children aged 6-11 years with uncontrolled severe atopic dermatitis (AD), 16 weeks of treatment with dupilumab resulted in substantial clinical benefit compared with placebo with an acceptable safety profile. However, longer-term safety and efficacy...
Journal Articles
Kompass Dermatol (2023) 11 (2): 76–77.
Published Online: 20 April 2023
...Felix Lauffer Background: Effective, well-tolerated oral psoriasis treatments are needed. Objective: To compare the efficacy and safety of deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, versus placebo and apremilast in adults with moderate to severe plaque psoriasis...
Journal Articles
Subject Area:
Dermatology
Kompass Dermatol (2023) 11 (1): 27–28.
Published Online: 14 March 2023
...Irina Blumenstein Gut microbiota dysbiosis is involved in the development of systemic lupus erythematosus (SLE). The safety and efficacy of fecal microbiota transplantation (FMT) for the treatment of SLE patients has not been explored. In this 12-week, single-arm pilot clinical trial of oral...
Journal Articles
Kompass Dermatol (2022) 10 (4): 184–185.
Published Online: 07 November 2022
... pemphigus by suppressing B-cell signaling. Objective: We investigated the efficacy and safety of tirabrutinib in patients with refractory pemphigus. Methods: This was a multicenter, open-label, single-arm phase 2 study of Japanese patients with refractory pemphigus receiving appropriate treatment...
Journal Articles
Subject Area:
Dermatology
Kompass Dermatol (2022) 10 (1): 12–13.
Published Online: 28 January 2022
...% versus 17.6%) and without LCT (38.7% versus 6.5%). Brentuximab vedotin improved median PFS versus physician’s choice in patients: with CD30min < 10% (16.7 versus 2.3 months), with CD30min ≥ 10% (15.5 versus 3.9 months), with LCT (15.5 versus 2.8 months) and without LCT (16.1 versus 3.5 months). Safety...
Journal Articles
Journal Articles
Subject Area:
Dermatology
Kompass Dermatol (2021) 9 (3): 142–143.
Published Online: 30 June 2021
..., endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements...
Journal Articles
Kompass Dermatol (2021) 9 (1): 14–15.
Published Online: 22 January 2021
..., quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements. Anti-interleukin 17 Drug survival Elderly Safety Psoriasis Abstract aus...